AKT1 and pancreatic neoplasm: In summary, our findings suggest that combined inhibition of PI3K/Akt/mTOR and Shh pathways will be beneficial for the treatment of pancreatic cancer by targeting CSCs, and further study of these pathway inhibition in the clinical setting is warranted.